JAFRON(SZ:300529)2025-01-21 11:04Financial Projections - The expected operating revenue for 2024 is projected to be between 278,700,000 and 259,500,000 CNY, representing a year-on-year growth of 35% to 45% compared to 192,234,820 CNY in the previous year[3]. - The net profit attributable to shareholders is expected to be between 80,000,000 and 86,000,000 CNY, indicating a significant increase of 83% to 97% from 43,649,220 CNY in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is anticipated to be between 74,520,000 and 80,520,000 CNY, reflecting a growth of 82% to 97% compared to 40,904,300 CNY in the previous year[3]. - Non-recurring gains and losses for 2024 are estimated to impact net profit by approximately 5,480,000 CNY, primarily from government subsidies and investment income, compared to 2,744,920 CNY in 2023[6]. Business Performance - The company has experienced favorable external policy conditions and has leveraged its technological and market advantages in blood perfusion, leading to strong business growth in nephrology, hepatology, and critical care[5]. - The company has implemented cost reduction measures, resulting in a decrease in the expense ratio, contributing to the substantial increase in net profit[5]. Financial Reporting - The financial data presented is based on preliminary estimates by the company's finance department and has not yet been audited by external auditors[4]. - The detailed financial data will be disclosed in the 2024 annual report, and investors are advised to make cautious decisions and be aware of investment risks[7].